相关临床试验
7
1 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
2017
进行中（未招募）
1
14.3%
已完成
5
71.4%
招募中
1
14.3%
暂无批准数据
- The Phase 2 MOONLIGHT-1 trial of JNJ-5120/PIPE-307 in major depressive disorder failed to meet its primary MADRS efficacy endpoint at Day 5 versus placebo. - The M1 receptor antagonist was well tolerated with no new safety signals, and Johnson & Johnson is still analyzing prespecified exploratory endpoint data. - The miss is the second Phase 2 failure for the molecule, following the VISTA trial in relapsing-remitting multiple sclerosis in 2025. - Analysts removed the asset from financial models, shifting Contineum's valuation focus to its wholly owned LPA1 antagonist PIPE-791 for idiopathic pulmonary fibrosis.
- The FDA approved Curium's Bexlutry, the first generic radioligand therapy, a copycat of Novartis' Lutathera that delivers radioactive lutetium to SSTR-positive neuroendocrine tumors. - The approval covers foregut, midgut and hindgut SSTR-positive neuroendocrine cancers and followed Curium's victory in a patent dispute with Novartis. - Arrowhead's dual-acting RNA interference therapy Aro-Dimer-Pa cut PCSK9 and APOC3 protein levels by 72% and 88% after a single dose in an early-stage trial. - Corbus reported CRB-913 produced up to 5 percentage points more weight loss than placebo at 12 weeks, but psychiatric side effects drove treatment discontinuations.
- The Phase 2 MOONLIGHT-1 trial of JNJ-5120/PIPE-307 did not meet its primary efficacy endpoint in adults with major depressive disorder, Contineum Therapeutics reported. - The trial assessed improvement from baseline in MADRS total score at Day 5 versus placebo; the M1 receptor inhibitor was well-tolerated with no new safety signals. - Johnson & Johnson, which develops the drug under a global license agreement, is analyzing prespecified exploratory endpoints to assess clinical relevance and next steps. - Contineum separately affirmed its Phase 2 PROPEL-IPF trial of PIPE-791, now with more than 55 sites across eight countries, and a cash runway through mid-2029.
- Contineum Therapeutics announced positive topline data from its Phase 1b trial of PIPE-791, demonstrating favorable safety and tolerability in 43 patients with chronic osteoarthritis pain or chronic low back pain. - The LPA1 receptor antagonist showed encouraging trends across multiple exploratory efficacy endpoints, with patients demonstrating numerically greater improvements in pain measures compared to placebo. - PIPE-791 was administered as a once-daily 10mg oral dose and represents a potential non-opioid treatment option for chronic pain conditions. - The results support further clinical investigation of PIPE-791 for chronic pain treatment, with the company contemplating next steps for additional clinical development.
- Contineum Therapeutics has initiated patient dosing in PROPEL-IPF, a global Phase 2 trial evaluating PIPE-791 for idiopathic pulmonary fibrosis, targeting 324 patients over 26 weeks with a primary endpoint of forced vital capacity change. - PIPE-791 demonstrates potential differentiation from Bristol Myers Squibb's competing LPA1 antagonist through achieving approximately 90% receptor occupancy at 1 mg daily dosing and showing no hypotension signal to date. - The company maintains financial runway through mid-2029 following a $93 million public offering, while also advancing PIPE-307 in partnership with Johnson & Johnson for major depressive disorder treatment. - Topline data from an exploratory PIPE-791 Phase 1b chronic pain trial is expected in Q2 2026, potentially supporting quality-of-life benefits in pulmonary fibrosis populations.
- Contineum Therapeutics' lead experimental drug PIPE-307 failed to meet primary and secondary endpoints in a mid-stage clinical trial for relapsing-remitting multiple sclerosis. - The study tested two different doses of PIPE-307 against placebo, with neither dose showing significant impact on the primary vision test endpoint despite acceptable safety profiles. - Company shares fell more than 12% in after-hours trading following the announcement, with the stock hovering around $12.20 per share. - Contineum plans to continue analyzing exploratory study objectives and present full results at medical meetings while remaining committed to developing therapies for inflammatory and fibrotic diseases.
- Spine BioPharma's SB-01 (vicatertide) failed to meet Phase III endpoints in 417 patients with degenerative disc disease, attributed to unexpectedly strong placebo effects at certain trial sites. - Persica Pharmaceuticals' PP353, a novel non-opioid intradiscal injection, achieved its primary endpoint in a Phase Ib trial, showing statistically significant pain reduction in 44 patients with chronic low back pain. - The chronic lower back pain pipeline includes over 10 companies developing more than 10 treatment therapies, with emerging candidates spanning from Phase I to Phase III development stages. - Recent regulatory activity includes FDA approval of Tonmya for fibromyalgia and IND authorization for Contineum's PIPE-791 targeting chronic pain conditions including low back pain.
- Contineum Therapeutics announced positive topline data from its Phase 1b PET trial of PIPE-791, an LPA1 receptor antagonist being developed for idiopathic pulmonary fibrosis, progressive multiple sclerosis, and chronic pain. - The trial successfully assessed the correlation between pharmacokinetics and LPA1 receptor occupancy using PET imaging in 12 healthy volunteers and four progressive multiple sclerosis patients. - Based on brain receptor occupancy data, the company expressed confidence in planned doses for future Phase 2 proof-of-concept trials, with researchers believing brain distribution patterns can predict lung receptor occupancy. - PIPE-791 represents part of Contineum's pipeline of oral small molecule therapies targeting neuroinflammatory and immunological indications with significant unmet medical needs.
- Contineum Therapeutics expects topline data from its PIPE-791 Phase 1b PET trial in Q2 2025 and PIPE-307 Phase 2 VISTA trial for relapsing-remitting multiple sclerosis in H2 2025, affirming its clinical development timeline. - The company has completed chronic toxicity studies for PIPE-791 to support upcoming Phase 2 trials in idiopathic pulmonary fibrosis and progressive multiple sclerosis planned for the second half of 2025. - With $190.7 million in cash and equivalents as of March 31, 2025, Contineum projects sufficient funding through 2027 to advance its pipeline of novel therapies targeting neuroscience, inflammation, and immunology indications.
- Contineum Therapeutics has completed enrollment of 168 patients in its Phase 2 VISTA trial evaluating PIPE-307 for relapsing-remitting multiple sclerosis (RRMS). - PIPE-307, a potentially first-in-class M1 receptor antagonist, aims to promote remyelination in RRMS patients by modulating oligodendrocyte precursor cell differentiation. - The randomized, double-blind, placebo-controlled trial will assess the safety and efficacy of PIPE-307, with topline data expected in the third quarter of 2025. - The VISTA trial is designed to measure clinical and imaging endpoints sensitive to changes in remyelination, potentially marking a new treatment approach for RRMS.
